Healthcare · Case StudyJan 20, 2026 · 5 min read

What If UNH Today Is Like MRF in February 2025?

A global giant facing a short-term reset — not a collapse. Here is why the parallel matters.
H
Himan Roshan Borah
The Investment Letter · Easy Equity
5 min read
$450B
UNH 2025 revenue
89.9%
Medical Cost Ratio Q3
2027
Recovery timeline

A Familiar Pattern

Imagine a powerhouse company suddenly hitting a rough patch. In February 2025, MRF's share price slipped to nearly ₹1,05,000, triggering fears that its best days were behind it. Yet nothing fundamental had changed. MRF hadn't lost its brand strength, distribution reach, or pricing power. What investors were seeing was a temporary earnings slowdown — a reset, not a collapse.

UnitedHealth Group, the largest healthcare company in the world, appears to be going through a comparable phase today. Despite revenues of about $450–455 billion in 2025, profits have weakened. The headline numbers look worrying — but much like MRF in early 2025, the underlying business remains intact.

This looks more like a short-term adjustment than a long-term decline.

— Easy Equity Analysis

What Caused the Short-Term Pain?

The slowdown at UnitedHealth is not due to a drop in healthcare demand. People continue to need medical care. Instead, the pressure stems from policy changes, higher-than-expected medical utilization, and underpriced health plans where the company assumed it could manage costs more effectively.

Medical expenses rose sharply, Medicare funding was reduced, and the impact of new cost frameworks such as the V28 risk model was underestimated. These factors point to execution and policy shocks — not a structural demand problem.

Key Metric
Optum Health's operating margin fell from over 8% last year to around 1% in Q3 2025 — but management is actively addressing this. Investments are being redirected toward AI-driven productivity and higher-margin services.

The Turnaround Strategy

In response, UnitedHealth's management has started taking corrective steps. The company is exiting unprofitable geographies and reshaping parts of its healthcare delivery model. Management has been transparent about the challenges — a positive sign for long-term investors.

By 2027, the company expects earnings growth to return to double digits, turning near-term pain into long-term opportunity. Medicaid is expected to stabilise by 2026, Medicare margins to recover gradually.

The Indian Parallel

For Indian investors, this situation is easier to understand by looking at large conglomerates such as Tata Steel or Reliance. These companies have faced temporary profit declines due to policy shifts, commodity cycles, or operational challenges — yet their core strengths remained intact. Once short-term shocks passed, they emerged stronger.

The central question: are current margin pressures permanent or a temporary squeeze? The answer will depend on execution.

— Easy Equity Analysis
← All Articles Follow on Substack →